Key result
Neuroleptic therapy can cause neuroleptic malignant syndrome, a rare complication requiring a high index of suspicion in primary care patients presenting with hyperthermia.
Physicians in primary care must maintain a high index of suspicion for neuroleptic malignant syndrome in patients taking neuroleptics who present with hyperthermia.
Supports vigilance for this rare syndrome in primary care hyperthermia; leaves open updated incidence and prevention data.
In recent years, there has been an increased use of neuroleptic agents in the primary care setting. Neuroleptic malignant syndrome (NMS) is a rare complication of neuroleptic therapy that can be missed if not suspected. This manuscript reviews the diagnosis and management of NMS in the primary care setting. There is a lack of prospective data, and most of the information is obtained from case series. Physicians need to have a high index of suspicion with regard to excluding NMS in patients taking neuroleptics and presenting with hyperthermia.
No takes yet. Share an insight, caveat, or question.
A 2004 study conducted a review in Neuroleptic Malignant Syndrome. Neuroleptic therapy was evaluated. Neuroleptic therapy can cause neuroleptic malignant syndrome, a rare complication requiring a high index of suspicion in primary care patients presenting with hyperthermia.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: